Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $230.00 Price Target at Truist Financial

Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) had its target price hoisted by Truist Financial from $220.00 to $230.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company's stock.

Several other research analysts also recently commented on the company. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price objective for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $189.40.

Remove Ads

Jazz Pharmaceuticals Trading Up 1.7 %

Shares of JAZZ traded up $2.36 during trading hours on Thursday, hitting $138.81. The company had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. The firm has a market cap of $8.43 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44. The stock's 50 day moving average price is $128.14 and its 200 day moving average price is $120.03. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $148.06.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares of the company's stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,193 shares of company stock valued at $3,533,122. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of JAZZ. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.